Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

about

Amniotic membrane application reduces liver fibrosis in a bile duct ligation rat model.Addressing liver fibrosis with liposomes targeted to hepatic stellate cells.

P2860

Q39946490-D665A38C-B747-4201-A53C-5A578DD2917F Q46890423-187AA6E4-1F6F-4C97-9CBF-95A5451F4ABE

P2860

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

Item

http://www.wikidata.org/entity/Q45105191

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

@en

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

@nl

type

Item

label

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

@en

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

@nl

prefLabel

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

@en

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

@nl

P1476

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

@en

P2093

Frederik Nevens

http://www.w3.org/2001/XMLSchema#string

Ingrid Van der Elst

http://www.w3.org/2001/XMLSchema#string

Johan Fevery

http://www.w3.org/2001/XMLSchema#string

Jos F van Pelt

http://www.w3.org/2001/XMLSchema#string

Marc Van de Casteele

http://www.w3.org/2001/XMLSchema#string

P2860

Low NO bioavailability in CCl4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: A comparison of two portal hypertensive rat models with healthy c

Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.

Anticoccidial activity of arprinocid and halofuginone.

Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow.

Hepatic stellate cells as a target for the treatment of liver fibrosis.

Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone.

Halofuginone: an inhibitor of collagen type I synthesis.

In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats.

Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats.

Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.

P304

502-509

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1478-3231.2004.0950.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tania Roskams

P577

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15482349

http://www.w3.org/2001/XMLSchema#string

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

about

P2860

P2860

Halofuginone can worsen liver fibrosis in bile duct obstructed rats.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698